Multiplexed inhibition of immunosuppressive genes with Cas13d for combinatorial cancer immunotherapy go.nature.com/4gYcS4Z

📢 Registration is now open for an exciting Gordon Conference on synthetic lethality organized by Ben Schwartz (GSK), Mathew Garnett (Sanger), and Francisca Vazquez (DepMap Director, Broad Institute) Highly recommended! Register here grc.org/synthetic-leth…

#PERSPECTIVE 🚨 Hahn, Vazquez & colleagues outline the current limitations and future strategies for enhancing the Cancer Dependency Map project. 👇 📖 bit.ly/4aGlBGw

🚨Exciting New Synthetic Lethal Target from #depmap!

(1/3) Excited to share our latest work using The Cancer Dependency Map to uncover a new synthetic lethality in two distinct patient populations! We found that SKI complex inactivation through two independent genomic alterations creates a dependency on PELO nature.com/articles/s4158…

🚨 New study! 🚨Excited to share our research on #translocationRCC #tRCC published in Nature Metabolism, in collaboration with @lironbarpeled. We reveal how the TFE3 fusion drives a key oxidative phosphorylation (OXPHOS) metabolic program in this kidney cancer. 1/ Dana-Farber News

Here's our latest - jointly with Riz Haq MD PhD lab & co-lead by Drs. Julia Schiantarelli, MD, Benamar, Park et al - studying why some tumors stop responding to immunotherapy. This continues to be a tough puzzle to solve, but important for science & patients alike...

CRISPRai simultaneously activates and represses two genes in single cells go.nature.com/4apFU9q rdcu.be/efe0E

An engineered Cas12a enables higher-order combinatorial functional genomic screens using CRISPR interference go.nature.com/3UTnSXM rdcu.be/ef95k

We examined the present and future of AI and translational cancer research for Cancer Cell - check out superstar Josephine Yates below for more on this perspective! Dana-Farber News

Great to see our work in the April 2025 issue of Molecular Cancer Therapeutics #KRAS

New review of The Current State & Roadmap for AI in Cancer Treatment Decisions in NEJM AI discusses potential of large language models/LLMs in treatment selection. By Olivier Elemento Sean Khozin, MD, MPH Cora Sternberg (subscription $) ai.nejm.org/doi/full/10.10…. NEJM AI EIC is Isaac Kohane

🖥️ 🧬 Detecting homologous recombination deficiency for breast cancer through integrative analysis of genomic data 🔗 buff.ly/2kAh3KA 🖊️ CaldasLab #CancerGenomics #BRCA1 #PARPi #MachineLearning

Here's our latest, led by superstars Josephine Yates & Dr. Camille Mathey-Andrews, jointly with Valentina Boeva and many more Dana-Farber News Broad Institute We studied primary & lethal esophageal cancer using multi[RNA, ATAC, spatial]-omics, see Josephine's tweets below for more!👇

Now in Cancer Cell our group reports the development of a first-in-class EGFR-directed KRAS G12V selective inhibitor. KRAS G12V mutations are the 2nd most common KRAS mutation in cancer, and there are still no approved inhibitors in the clinic. We address two major challenges

Targeting the Hippo pathway in cancer nature.com/articles/s4157… This new Review discusses emerging Hippo pathway-targeted therapies for cancer, particularly those that target TEAD DNA binding proteins and their interaction with the YAP/TAZ transcription co-activators

We are all somatic mutation mosaics. "There are trillions of cells in a human body and so the total number of somatic mutations acquired in a single individual may well exceed quadrillions, millions of times the size of the human genome." nature nature.com/articles/s4158…

Thrilled to share our paper now out in nature that correlates inactivating PPP2R1A somatic mutations with improved survival for patients with cancer receiving immunotherapy, with exciting prelim mechanistic insights! Amir Jazaeri Linghua Wang, MD, PhD Yibo nature.com/articles/s4158…

A new #ScienceReview looks at a different approach to drug discovery that may enable drugging of unconventional targets through stabilization of macromolecular complexes with molecules known as “LOCKTACs.” Learn more: scim.ag/4lAiKmF

15 years in the making, we confirmed that mitochondria -the powerhouse of the cell- have an unusual localization in patients who experience psychosis (including schizophrenia and bipolar disorders). You’ll never guess what kind of patient cells we used to make this discovery...🧵